Vitamed, Rekah Group

Company Overview

Snapshot

Founded in January 1947, Vitamed, Rekah Group operates with 11–50 employees. The company became public on TASE in January 1994, marking a significant milestone in its corporate history.

Business overview

Vitamed, Rekah Group is a generic pharmaceutical manufacturer that operates across the entire value chain, including production, R&D, marketing, sales, distribution, import, and export. The company's portfolio encompasses approximately 280 generic prescription and over-the-counter drugs, dermo-cosmetics, vitamins, and nutritional supplements. It focuses on four core areas: steroids, antibiotics, ophthalmic medications, and over-the-counter drugs, serving global markets within the Health Tech & Life Sciences sector.

Company Intelligence Q&A

What is the primary focus of Vitamed, Rekah Group's product portfolio?

Vitamed, Rekah Group's product portfolio focuses on four core fields: steroids, antibiotics, ophthalmic medications, and over-the-counter drugs, alongside dermo-cosmetics, vitamins, and nutritional supplements.

When did Vitamed, Rekah Group become a public company?

Vitamed, Rekah Group became public on TASE in January 1994.

What are Vitamed, Rekah Group's strategic goals for international expansion?

Vitamed, Rekah Group aims to increase its international presence by focusing on out-licensing, in-licensing, establishing new partnerships, and executing mergers and acquisitions.

Where does Vitamed, Rekah Group conduct its research and development activities?

Vitamed, Rekah Group operates research and development laboratories at its production sites in Holon and Binyamina.

What is the range of products offered by Vitamed, Rekah Group?

Vitamed, Rekah Group offers a wide range of 280 generic prescription and over-the-counter drugs, dermo-cosmetics, vitamins, and nutritional supplements.